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Abstract
Background: The gold standard to assess hyperbilirubinemia in neonates remains the serum
bilirubin measurement. Unfortunately, this is invasive, painful, and costly. Bilimed®, a new
transcutaneous bilirubinometer, suggests more accuracy compared to the existing non-invasive
bilirubinometers because of its new technology. It furthermore takes into account different skin
colours. No contact with the skin is needed during measurement, no additional material costs
occur. Our aim was to assess the agreement between the Bilimed® and serum bilirubin in preterm
and term infants of different skin colours.
Methods: The transcutaneous bilirubin measurements were performed on the infant's sternum
and serum bilirubin was determined simultaneously. The agreement between both methods was
assessed by Pearson's correlation and by Bland-Altman analysis.
Results: A total of 117 measurement cycles were performed in 99 term infants (group1), further
47 measurements in 38 preterm infants born between 34 - 36 6/7 gestational weeks (group 2), and
finally 21 measurements in 13 preterm infants born between 28 - 33 6/7 gestational weeks (group
3). The mean deviation and variability (+/- 2SD) of the transcutaneous from serum bilirubin were:
-14 (+/- 144) μmol/l; -0.82 (+/- 8.4) mg/dl in group 1, +16 (+/- 91) μmol/l;+0.93(+/- 5.3) mg/dl in
group 2 and -8 (+/- 76) μmol/l; -0.47 (+/- 4.4) mg/dl in group 3. These limits of agreement are too
wide to be acceptable in a clinical setting. Moreover, there was to be a trend towards less good
agreement with increasing bilirubin values.
Conclusion: Despite its new technology the Bilimed® has no advantages, and more specifically no
better agreement not only in term and near-term Caucasian infants, but also in non-Caucasian and
more premature infants.
Background
The incidence of neonatal hyperbilirubinemia has been
reported to be between 30-60% in full-term newborns
and nearly 100% in premature infants [1]. The accurate
measurement of bilirubin concentrations is essential for
the diagnosis of hyperbilirubinemia and for guiding the
clinician with regard to treatment. Although flawed by
some imprecision, the gold standard remains the meas-
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urement of serum bilirubin concentration. This method
however is invasive, painful and costly in terms of work-
load, time and money. Moreover, repeated blood sam-
plings may lead to significant blood loss, which may be of
particular concern in preterm infants. Trying to overcome
these drawbacks, non-invasive methods of bilirubin
measurements have been proposed. Transcutaneous
bilirubinometry has been shown to correlate with serum
bilirubin concentration in term infants [2-8]. In preterm
infants transcutaneous bilirubinometry is less accurate
than in term infants, as results are affected by the imma-
ture skin and by a different albumin-to-bilirubin binding
[6,9,10].
Race, gestational age (GA), and body weight are other fac-
tors that may decrease the accuracy of the transcutaneous
bilirubin (TcB) measurements. Most importantly, the
most widely used transcutaneous devices tend to underes-
timate bilirubin values, particularly at higher concentra-
tions [11,12].
Recently, a new 2nd generation transcutaneous bilirubi-
nometer (Bilimed®) has been developed, and based on a
new technology using a five-wavelength analysis, a higher
measurement accuracy has been suggested, independently
of gestational age and skin colour. Only one study has so
far been published with this new device in white Cauca-
sian infants born near term or at term [13]. The aim of our
study was to determine the accuracy and agreement of this
new transcutaneous device with serum bilirubin concen-
tration in newborn infants of different gestational ages
and different skin colour.
Methods
This study was carried out in the maternity ward and in
the neonatal intensive care unit of the University Hospital
Zurich. We intended to include 100 healthy term (mater-
nity ward) and 50 preterm infants born between 28 0/7
and 36 6/7 weeks of gestation (maternity ward, interme-
diate care and NICU). We also aimed enrolling infants
with different skin colours (Caucasian and non-caucasian
origin). No infant had been treated with phototherapy
until enrolment. The study was approved by the local eth-
ics committee, and parental consent was obtained.
The Bilimed® (Nufer Medical, Guemligen/Berne, Switzer-
land) is a microprocessor controlled device with 10 LEDs
(3 green, 3 yellow, 2 blue, 2 red) which do not move dur-
ing measurement and which is based on a five-wavelength
analysis. Based on a minimum of two TcB readings, this
device calculates the patient's bilirubin concentration and
retains the best result. The bilirubin concentration is
clearly displayed on the touch screen in μmol/l or mg/dl.
It takes into account different ethnic skin colours, it does
not necessarily need contact with the skin for measure-
ment, and it generates no additional material costs for
each measurement. In order to keep the measurement dis-
tance between the LEDs and the skin constant, a soft ring
provided by the manufacturer was used, and the Bilimed®
was applied on the sternum of the infants. For our study,
the transcutaneous bilirubin concentration was measured
three times. This was done by the same person and imme-
diately before or within 15 minutes after capillary blood
sampling for serum bilirubin concentration measure-
ments. The latter determinations were performed in the
clinical chemistry laboratory of the University Hospital
Zurich (Diazo method, Total Bilirubin Special COBAS
Integra Neonatal, Roche Diagnostics, Basle, Switzerland).
For our clinical chemistry, the variation coefficient for
neonatal capillary bilirubin concentration measurements
amounts to 4.6%.
For analysis, the mean of the three transcutaneous
bilirubin readings was taken and then compared with the
serum bilirubin concentration. The coefficient of varia-
tion (CV) of these three measurements was calculated for
the three groups. The relationship between transcutane-
ous and serum bilirubin values was determined using
simple linear regression analysis. The strength of this rela-
tionship was quantified by using the Pearson correlation
coefficient r. The agreement between both methods was
assessed by the method of Bland-Altman. A multiple lin-
ear regression analysis was performed to identify con-
founders to predict serum bilirubin. Excel (Microsoft
Office Professional 2003, SP3) and StatView (Version
5.01 for Windows, SAS Inc., Carry, NC, USA) were used
for statistical calculations and graphs. Statistical signifi-
cance was defined for p < 0.05, with a maximum risk of α-
error set at 5%.
Results
A total of 99 term and 51 preterm infants were included
in the study, out of whom 90 were of Caucasian origin
and 60 were non-Caucasian (36 of Hispanic or Middle-
East, 9 of African and 15 of Asian origin). The group of
preterm infants was subdivided into more mature prema-
ture infants born between 34 0/7 and 36 6/7 weeks gesta-
tional age (group 2) and the more premature infants born
between 28 0/7 and 33 6/7 weeks gestation (group 3). 111
measurements were performed in 99 term infants (group
1), 47 measurements in 38 preterm infants of group 2 and
21 measurements in 13 preterm infants allocated to group
3. The patient characteristics are shown in Table 1.
The relationship between serum bilirubin concentration
and transcutaneous bilirubin concentration for the 3 ges-
tational age groups was y = 0.54x + 75 for group 1, y =
0.38x + 127 for group 2, and y = 0.15x + 61 for group 3.
Figure 1A depicts this relationship for all term infants (y =
111; y = 0.54x+77, R2 = 0.52; p > 0.01), and Figure 1B forBMC Pediatrics 2009, 9:70 http://www.biomedcentral.com/1471-2431/9/70
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all preterm infants (group 2 and 3; y = 68; y = 0.37x + 110;
R2 = 0.48; p < 0.001). The same relationship is shown for
all Caucasian infants and for all non-Caucasian infants in
Figure 2A (n = 126; y = 0.51x+85; R2 = 0.40; p < 0.01), and
Figure 2B (n = 59; y = 0.50x+82; R2 = 0.48; p < 0.001)
respectively.
The Pearson's correlation coefficients r for the three
groups were 0.722 (p < 0.001) for the group 1; 0.370 (p =
0.01) for group 2; and 0.521 (p = 0.016) for group 3. The
variability of the three readings from a single site given
infant is assessed by the coefficient of variation, which was
0.063 for group 1, 0.061 for group 2, and 0.062 for group
3.
A Bland-Altman plot of all comparisons is shown in Fig-
ures 3, 4 and 5. The mean deviation and variability (+/-
2SD) between the transcutaneous values and serum
bilirubin in group 1 was: -14 (+/- 144) μmol/l (Figure 3),
+16 (+/- 91) μmol/l in group 2 (Figure 4), -8 (+/- 76)
μmol/l in group 3 (Figure 5). Figure 6 depicts the agree-
ment between TcB and total serum bilirubin for Cauca-
sian infants (white rectangles, mean deviation 16;
variability +/- 121), and for non-Caucasian infants (black
diamonds, mean deviation variability +/- 174).
A multiple stepwise linear regression analysis to predict
serum bilirubin revealed birth weight (t-value 3.4, p <
0.001) as a confounding factor in addition to Bilimed val-
ues (t-value 10.7, p < 0.001), but not skin colour (t-value
-0.05, p = 0.38), nor gestational age (t-value -0.05, p <
0.96).
Discussion
Assessing a new 2nd generation transcutaneous bilirubi-
nometer Bilimed®, our study shows that the correlation
and the agreement between serum and transcutaneous
bilirubin measurements with the Bilimed® does not confer
any advantage over other transcutaneous devices. On the
contrary, this device performs slightly worse when com-
pared to the BiliCheck®  or to the Minolta-JM 103®
[2,8,10,13-16]. Recently, De Luca et al. (2008) found that
in comparison to Bilimed®, there was a better correlation
between BiliCheck® and total serum bilirubin. This group
performed their measurements only in white Caucasian
full-term or near-term infants with a gestational age >34
weeks [13]. Our study adds to the available knowledge in
that it provides also data on the performance of the Bil-
imed® in non-Caucasian, and also in younger preterm
infants.
Term infants
In full-term infants, a good correlation between transcuta-
neous and conventionally determined serum bilirubin
values was shown in different studies [12,16-19]. Other
authors concluded, that TcB measurements cannot accu-
rately predict serum bilirubin and that most of the trans-
cutaneous devices have limitations at higher bilirubin
values [8,11,12,20]. Beck and co-workers, investigating
the BiliCheck®, pointed out, that the limits of agreement
were too wide, and these authors concluded that TcB
measurement can only be recommended as a screening
tool [20]. Similary, the calculated limits of agreements are
too wide to be acceptable in a neonatal clinical setting in
order to use the Bilimed® instead of Bilirubin measure-
ments. Moreover, and as seen in Figure 3 the observed
trend towards a worse agreement with increasing bilirubin
values is of clinical concern.
Preterm infants
Several studies have been performed in preterm infants,
mainly enrolling healthy preterm babies. Our data do not
confirm previous findings of a strong positive linear rela-
tionship between TcB measurements and plasma
bilirubin concentrations in preterm infants [4,9,21-24].
The preterm infants in our study were divided into two
groups with a cut-off at 34 0/7 weeks. The reason for sub-
dividing this group was that the most very premature
infants clinically clearly represented a separate group by
being sicker or needing support (eg. parenteral feeding,
coffein, oxygen, etc.), and thereby, in addition to the
younger GA per se, were at higher risk for bilirubin
encephalopathy. In both sub-groups, the relationship
between transcutaneous and serum bilirubin was less
strong in comparison to the studies stated above. Com-
paring the regression equation of all preterm infants (Fig-
Table 1: Patient characteristics of the study group (TSB = total serum bilirubin)
Group 1 (n = 99) Group 2 (n = 37) Group 3 (n = 13)
median range median range median range
Gestation (wk) 39.1 37-42.3 36 34.1-36.5 30.3 29-32.2
Birth weight (g) 3300 2510-4950 2362.5 1570-3020 1360 1160-1790
Postnatal age(d) 4 2-12 4 2-7 5 2-11
TSB (μmol/l)
(mg/dl)
223
13
35-349
2-8.4
181
10.6
95-262
5.6-15.3
195
11.4
81-224
4.7-13.1
Bilimed (μmol/l)
(mg/dl)
198
11.6
50-343
2.9-20
202
11.8
99-264
5.8-15.4
195
11.4
76-256
4.4-14.9BMC Pediatrics 2009, 9:70 http://www.biomedcentral.com/1471-2431/9/70
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ure 1B) with the term group (Figure 1A), the constant for
the preterm infants was greater than for term infants (110
vs. 77). The correlation coefficient R2 (0.15) and the Pear-
son's coefficient r (0.39) showed a worse agreement than
for term infants (R2 = 0.52, and r = 0.72 respectively). In
comparison, De Luca et al. found a R2-value of 0.20 and r-
value of 0.45 for the whole group of term and near-term
infants [13].
Several confounding factors have been described previ-
ously, such as gestational age, postnatal age or skin condi-
tion [6,9,21,23,25]. Karolyi et al. demonstrated that only
TcB measurements and birth weight were independently
associated with the plasma bilirubin concentration in a
group of very low birth weight (VLBW) infants <1500 g
[22]. Gestational age, postnatal age, intrauterine growth
retardation (IUGR) and hematocrit did not turn out to be
Bilimed® values on the sternum against total serum bilirubin  values in term infants (Figure 1A, group 1, n = 111) and in  preterm infants (Figure 1B, group 2 and 3, n = 68) Figure 1
Bilimed® values on the sternum against total serum 
bilirubin values in term infants (Figure 1A, group 1, n 
= 111) and in preterm infants (Figure 1B, group 2 and 
3, n = 68). Continuous linear regression line; dotted line of 
identity.
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Bilimed® values on the sternum against total serum bilirubin  values in Caucasian (Figure 2A, n = 126) and non-caucasian  (Figure 2B, n = 59) Figure 2
Bilimed® values on the sternum against total serum 
bilirubin values in Caucasian (Figure 2A, n = 126) and 
non-caucasian (Figure 2B, n = 59). Continuous linear 
regression line; dotted line of identity.
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of significant importance. Knüpfer et al. reported correla-
tion coefficients ranging from 0.47-0.67 in the age group
of infants born at 23-30 weeks [9].
Importantly, we observed many difficulties with the meas-
urements in the group 3. Factors accounting for these
measurement difficulties were smaller body size with a
narrow thorax area as a sampling site, and the fact that
many of these very preterm infants were studied while still
having a respiratory distress syndrome with retractions
and tachypnoea. The rapidly and extensively moving sam-
pling site made transcutaneous measurements cumber-
some and even virtually impossible in some of this tiny
infants. If feasible at all, the time needed for tcB measure-
ment was two or three times longer to get a reading of
acceptable quality. Obviously, the advantage of the Bil-
imed® device of not needing to touch the infant's skin did
not overcome these problems. Therefore we stopped the
transcutaneous measurements in this gestational age
group after 13 patients with, as a consequence, a substan-
tional higher number of more mature preterm infants
(group 2) within a total number of 51 preterm infants
studied.
Different skin colours
Importantly, for both Caucasian and non-Caucasian
infants, the constant in the regression equation was far
Bland-Altman plot showing agreement between total serum  bilirubin values and the Bilimed® values for group 1 Figure 3
Bland-Altman plot showing agreement between total 
serum bilirubin values and the Bilimed® values for 
group 1. The lines represent mean difference (-14) and ± 
2SD of the difference (+/- 144)
-200
-150
-100
-50
0
50
100
150
200
0 100 200 300 400
Serum bilirubin (μmol/l)
D
i
f
f
e
r
e
n
c
e
 
B
i
l
i
S
e
r
 
-
 
B
i
l
i
m
e
d
Bland-Altman plot showing agreement between total serum  bilirubin values and the Bilimed® values for group 2 Figure 4
Bland-Altman plot showing agreement between total 
serum bilirubin values and the Bilimed® values for 
group 2. The lines represent mean difference (+16) and ± 
2SD of the difference (+/- 91)
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Bland-Altman plot showing agreement between total serum  bilirubin values and the Bilimed® values for group 3 Figure 5
Bland-Altman plot showing agreement between total 
serum bilirubin values and the Bilimed® values for 
group 3. The lines represent mean difference (-8) and ± 2SD 
of the difference (+/- 76)
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different from zero, but interestingly, they were not differ-
ent from each other. Moreover, both the Pearson's corre-
lation coefficient r and R2 were similar for both groups
(Figure 2A and 2B). When the agreement between both
groups was assessed by Bland-Altman analysis, there were
a few more TSB measures outside the limits of agreement
in the Caucasian infants, but the limits of agreement were
much wider in the non-Causasian infants (+/- 174 vs. +/-
121) (Figure 6). In order to asses the influence of gesta-
tional age, birth weight and ethnicity as confounding fac-
tors, we performed a multiple linear regression analysis
which showed that birth weight is a confounding factors
but not skin colour, nor gestational age.
The accuracy of TcB readings may also differ when com-
paring different ethnic groups and the hope that TcB
measurements would be independent of both race and
pigmentation has not been fulfilled yet [5,8,9,17]. In one
study by Bhutani and co-workers the correlation between
BiliCheck® TcB and high performance liquid chromatogra-
phy (HPLC) measurements of the total serum bilirubin
(TSB) in African-American infants was as good as in Cau-
casian infants, whereas TcB measurements by the Minolta
JM-103 tended to overestimate the TSB measurements in
African-American [2,16]. In the other ethnic groups how-
ever (East Asian, Middle Eastern, Indian/Pakistani, His-
panic), Minolta JM-103® measurements were similar to
the TSB measurements [26,27]. Slusher et al showed a
good agreement between BiliCheck® and TSB in indige-
nous African infants [28]. In our study the agreement
between serum bilirubin values and Bilimed® in non-
white infants (Hispanic, Middle East, African and Asian)
was not affected by skin colour when compared with
white infants.
Performance, site of sampling and serum bilirubin 
measurement
As it has been shown that the accuracy of the measure-
ments decreases when performed by several investigators,
we took care that all measurements were performed by
one person solely, and always over the infant's sternum
[11,14,29]. Choosing the sternum as sampling site is due
to the large measurement area of the Bilimed® instrument
making measurement over the forehead more difficult,
especially when studying more premature infants due to
their smaller size or to nasal CPAP bonnet. Maisels et al.,
using the JM-103 Jaundice Meter, performed measure-
ments over the forehead and sternum in 475 infants and
found a higher correlation for the values assessed over the
sternum [16]. Because the forehead is exposed to ambient
light, this can lead to underestimation of TSB values,
while the sternum is nearly always covered [5,30]. Meas-
urements over the sternum was therefore considered the
better choice for our measurements in our study. For the
purpose of this study, we determined serum bilirubin con-
centrations in our central hospital lab. Although we use
our own assay on the NICU (ABL 835 Flex, Radiometer,
Copenhagen, Denmark) for the daily routine with the
advantage of being faster, less labor-intensive and less
expensive, the central laboratory remains our 'gold stand-
ard' as it regulary participates in multi-centre quality
assessments. In order to minimize errors in the pre-analyt-
ical phase, the samples were shielded against light and
high-speed internal pneumatic delivery system allowed
for prompt measurement.
Conclusion
Our results show that, despite its new technology the new
transcutaneous bilirubinometer Bilimed® has no clinical
advantages, and more specifically no better agreement
with the serum bilirubin compared with the existing non
invasive bilirubinometers. It remains to be shown in stud-
ies including a greater number of infants of different eth-
nic background with different skin colours if the Bilimed®
performs better in these situations when compared in a
head-to-head testing to other transcutaneous devices.
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